Glial cell-derived neurotrophic factor (GDNF), first purified from glial cell culture medium, immediately attracted the interest of researchers due to its ability to enhance survival of midbrain dopaminergic neurons. This property suggested its therapeutic potential for Parkinson’s disease as a socially significant disease. Numerous academic and preclinical studies in animal models supported this hypothesis, but clinical trials yielded conflicting results. For this reason, GDNF is not currently used clinically. However, robust and perspective results in experiments justify further research and overcoming the causes of absent therapeutic effect. Research of GDNF gene alternative splicing products has emerged as a promising avenue. Several GDNF isoforms exhibit effects similar to those of GDNF and differ by smaller size and less dose-response relationship. This makes small GDNF isoforms potentially successful as therapeutic components for some CNS diseases.
Parshina et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: